Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21875204 | 0.94 | CHEK1 (0.46) | SYKCHEK1STK17ASTK17BFLT3 | |
| SCHEMBL21451013 | 0.94 | FERMT2 (0.37) | CHEK1FLT3HDAC1JAK2NQO2 | |
| SCHEMBL21450996 | 0.93 | SYK (0.41) | SYKCHEK1STK17ASTK17BFLT3 | |
| SCHEMBL30089846 | 0.93 | SYK (0.41) | SYKCHEK1STK17ASTK17BFLT3 | |
| SCHEMBL30089850 | 0.86 | PRKCI (0.38) | SYKHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21875232 | 0.86 | PRKCI (0.38) | SYKHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21451014 | 0.86 | MPO (0.35) | FLT3HDAC1JAK2HDAC6HDAC8 | |
| SCHEMBL21450995 | 0.82 | RAD52 (0.42) | FLT3HDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL21450994 | 0.82 | PDE5A (0.45) | JAK2APP | |
| SCHEMBL21451010 | 0.82 | HDAC3 (0.36) | FLT3HDAC1HDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | 3SM BIOTRON INC. (TW) | 2022-05-17 | — | — | US | disclosed |
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | 3SM BIOTRON INC. (TW) | 2022-05-17 | — | — | US | disclosed |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | Sagabio Co., Ltd. (TW) | 2020-04-30 | — | — | US | disclosed |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | Sagabio Co., Ltd. (TW) | 2020-04-30 | — | — | US | disclosed |
| WO-2019191896-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | 3SM BIOTRON INC. (CN) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332476-B2 | Fms-like tyrosine kinase inhibitors | FLT3, FLT4, FLT1 | SYK 74/4885CHEK1 575/4885STK17A 98/4885 |
| US-20200131194-A1 | FMS-LIKE TYROSINE KINASE INHIBITORS | FLT3, FLT4, FLT1 | SYK 74/4885CHEK1 575/4885STK17A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.